Photo by Chokniti Khongchum on Pexels

San Diego’s Iambic, a biotech company pioneering AI-driven drug discovery, has secured $100 million in funding. The investment will fuel clinical trials for their cancer drug candidates, representing a pivotal moment for AI’s role in pharmaceutical development. Iambic’s AI platform focuses on identifying small molecules with enhanced safety and efficacy. Their lead compound, IAM1363, is engineered to selectively target HER2, a key cancer driver, while mitigating the toxic side effects often seen in similar treatments. This precision underscores the transformative potential of AI in creating more effective and targeted therapies.